Today: 21 May 2026
Browse Category

NASDAQ:RR 6 October 2025 - 9 January 2026

Richtech Robotics (RR) stock rises again in premarket as CES “Dex” demo keeps traders watching

Richtech Robotics (RR) stock rises again in premarket as CES “Dex” demo keeps traders watching

Richtech Robotics shares rose 1% in premarket trading Friday after a 14.9% surge Thursday, driven by attention from a CES demo of its humanoid robot “Dex.” The company is operating under an SEC extension to file its annual report, projecting a wider net loss and $5.1 million in fiscal 2025 revenue. Investors are watching for CES updates and signs of new deals as the event ends.
9 January 2026
··
Richtech Robotics (RR) Stock Jumps on Robotics Policy Buzz and AI Deals – Latest News and 2025 Outlook (Dec. 4, 2025)

Richtech Robotics (RR) Stock Jumps on Robotics Policy Buzz and AI Deals – Latest News and 2025 Outlook (Dec. 4, 2025)

Richtech Robotics shares surged 18.54% to $4.22 at Wednesday’s close, trading 86.5 million shares after reports the Trump administration may boost U.S. robotics through executive action. Pre-market quotes Thursday show the stock up again near $4.26. Short interest remains high at over 10% of free float. The stock is up more than 400% year-over-year despite recent volatility.
4 December 2025
···
Richtech Robotics (NASDAQ: RR) Deep Dive — Why This Small‑Cap Robot Maker Is Turning Heads and Stirring Controversy in 2025

Richtech Robotics (NASDAQ: RR) Deep Dive — Why This Small‑Cap Robot Maker Is Turning Heads and Stirring Controversy in 2025

Richtech Robotics stock jumped nearly 20% to $6.18 on Oct. 3, 2025, after new service agreements with AutoNation and a global retailer. The company posted a $4 million Q3 loss on $1.2 million revenue but held over $85 million in cash. Short-seller Capybara Research accused Richtech of misrepresenting partnerships. H.C. Wainwright raised its price target to $6, while consensus remains around $4.50.
6 October 2025
··

Stock Market Today

  • SpaceX Files for Largest IPO Ever, Aiming to Raise $80 Billion
    May 20, 2026, 7:07 PM EDT. Elon Musk's SpaceX has filed paperwork for an initial public offering (IPO) expected to be the largest in history, potentially raising about $80 billion. This would surpass Saudi Aramco's 2019 record of $29 billion and could value SpaceX at over $1 trillion. Musk controls 85% of voting power, potentially becoming the world's first trillionaire. The company, known for reusable rockets and its satellite internet service Starlink, merged with Musk's AI firm xAI last year and plans ambitious projects including orbital data centers and moon bases. The IPO highlights the growing investor interest in space and AI-related industries, possibly setting the tone for a wave of tech IPOs including OpenAI and Anthropic.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop